iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP) | BTEKRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 25.9 | -0.4 | -10.5 | 4.2 | 2.4 | |
+/-Cat | -0.1 | 8.6 | -2.7 | 5.5 | 0.1 | |
+/-B’mrk | -7.0 | -0.7 | -13.0 | -3.1 | -6.1 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
Closing Price 26/04/2024 | GBX 477.60 | |
Day Change | -1.69% | |
Morningstar Category™ | Sector Equity Biotechnology | |
Volume | 12536 | |
Exchange | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BYXG2H39 | |
Fund Size (Mil) 25/04/2024 | USD 475.60 | |
Share Class Size (Mil) 25/04/2024 | USD 442.05 | |
Ongoing Charge 18/04/2024 | 0.35% |
Investment Objective: iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP) | BTEK |
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
- - | ||
Inception Date 19/10/2017 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP) | BTEK | 25/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 8.60 |
Vertex Pharmaceuticals Inc | Healthcare | 8.26 |
Regeneron Pharmaceuticals Inc | Healthcare | 8.06 |
Gilead Sciences Inc | Healthcare | 7.91 |
AstraZeneca PLC ADR | Healthcare | 4.88 |
Increase Decrease New since last portfolio | ||
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP) | BTEK |